Plain-English translation of NCT07635758 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called human placental-derived 3D mesenchymal stem cells (Guojianqingke) to see if it can safely help people recover from acute ischemic stroke—a type of stroke caused by a blood clot. Researchers will first test different doses to find the safest amount, then test whether this medication actually helps patients recover compared to a placebo. The study will follow participants for nearly two years to see how well the treatment works and watch for any side effects.
Acute ischemic stroke can cause serious, lasting disability, and current treatment options are limited, especially for patients who cannot receive other therapies like clot-busting drugs. This trial exists to explore whether this medication, made from stem cells that have special healing properties, might help the brain recover after a stroke.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be screened within 72 hours of your stroke and, if enrolled, receive a single injection of either the stem cell medication or placebo through an IV. You will then return for follow-up visits over the next two years so doctors can monitor your recovery, check for side effects, and measure how well you're doing compared to before the stroke. The study involves safety tests, imaging scans, and neurological exams to track your progress.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
China